Articles Related to ACG
Croscarmellose Sodium Efficiency in the Development of a Generic Capsule Formulation of Piroxicam, Comparable Dissolution Profile to the Innovator Product, Feldene
The objective of this study was to evaluate the encapsulation performance of Croscarmellose sodium, a superdisintegrant in a low-dose, poor-solubility drug formulation and the in-vitro dissolution performance of the Piroxicam capsules. Preparation, characterization and evaluation of the effects of the different concentrations of carmellose sodium and the amount of dried starch on in-vitro dissolution of Piroxicam capsules. Piroxicam was chosen for its very low solubility in biological fluids, which result in poor systemic bioavailability after oral administration. Piroxicam can be categorized as Class II drugs according to the Biopharmaceutics Classification System.
Editorial Board Members Related to ACG
Esam Z. Dajani
Adjunct Professor of Medicine
Loyola University
USA
Loyola University
USA
MASSIMO RUGGE
Professor
Department of Pathology
Padova University
Italy
Department of Pathology
Padova University
Italy
Danelina Vacheva
Department of Physical Medicine, Rehabilitation
Pleven Medical University
Bulgaria
Pleven Medical University
Bulgaria
Moinuddin Sarker
Natural State Research Inc.
Stamford, Connecticut
United States
Stamford, Connecticut
United States
Shirley Mcilvenny
Professor
Department of Health and Nutrition
National Institute of Integrative Medicine
Australia
Department of Health and Nutrition
National Institute of Integrative Medicine
Australia